Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity.

Abstract

Table S1. Technical parameters of the magnetic resonance imaging (MRI) scans. Table S2. Clinical and demographic characteristics of the MS cohort at baseline and at endpoint. Table S3. Baseline plasma and cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels. Table S4. Associations between baseline plasma and CSF neurofilament light chain (NfL) levels to baseline and longitudinal whole-brain and regional fractional brain fractions and MS lesions. Table S5. Clinical and demographic characteristics of the MS cohort at baseline for the stratified groups according to T1 lesion accrual and neurofilament light chain levels. Table S6. Differences in baseline brain fraction measures in patients stratified according to T1 lesion accrual and neurofilament light chain (NfL) levels. Table S7. Cluster tables for the left and right hemisphere. Table S8. Associations between baseline plasma NFL levels with longitudinal whole and regional brain fraction measures for the stratified groups according to T1 lesion accrual and neurofilament light chain levels. Figure S1. Flow chart of patient eligibility for the study. Figure S2. Correlation between plasma and cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels. Figure S3. Associations between baseline plasma and cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels to baseline thalamic fractional brain fraction and MS lesion measures. Figure S4. Associations between baseline plasma and cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels to future whole and regional fractional brain fraction and MS lesion measures. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.